![Kristina Sjöblom Nygren](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 19 811 $ al 30/06/2026
Kristina Sjöblom Nygren is currently an Independent Director at Infant Bacterial Therapeutics AB since 2018.
Former positions include Chief Medical Officer at Egetis Therapeutics AB from 2021 to 2026, Chief Medical Officer, EVP & Head-Development at Santhera Pharmaceuticals Holding AG from 2017 to 2020, Vice President & Head-Clinical Development at Swedish Orphan Biovitrum AB, Group Director-Development at AstraZeneca AG from 2007 to 2008, and Medical Director at Pfizer AG from 1998 to 2003.
Education includes a doctorate from Karolinska Institutet.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
EGETIS THERAPEUTICS AB 0,01 % | 31/12/2025 | 32.498 ( 0,01 % ) | 19 811 $ | 30/06/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| INFANT BACTERIAL THERAPEUTICS AB | Director/Miembro de la Junta | 15/05/2018 |
| Empresas | Cargo | Fin |
|---|---|---|
| EGETIS THERAPEUTICS AB | Director Técnico/Científico/I+D | 30/04/2026 |
| SANTHERA PHARMACEUTICALS HOLDING AG | Director Técnico/Científico/I+D | 31/12/2020 |
Astrazeneca AG | Corporate Officer/Principal | 01/01/2008 |
Pfizer AG | Director Técnico/Científico/I+D | 01/01/2003 |
| SWEDISH ORPHAN BIOVITRUM AB | Corporate Officer/Principal | - |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 7 |
|---|---|
Karolinska Institutet
 Karolinska Institutet Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
Astrazeneca AG | |
Pfizer AG | |
Swedish Orphan Biovitrum AB
 Swedish Orphan Biovitrum AB Pharmaceuticals: MajorHealth Technology Manufactures and supplies pharmaceuticals and orphan drugs in the areas of hematology, immunology and specialty care | Health Technology |
Egetis Therapeutics AB
 Egetis Therapeutics AB Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
Infant Bacterial Therapeutics AB
 Infant Bacterial Therapeutics AB Pharmaceuticals: MajorHealth Technology Develops drugs for the treatment of gastroschisis | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
MarketScreener is also available in this country: United States.
Switch edition
Elige MarketScreener 
